Navigation Links
Insmed to Present at Collins Stewart Fourth Annual Growth Conference
Date:7/9/2008

RICHMOND, Va., July 9 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced today that Steve Glover, President Insmed Therapeutics, will present at the Collins Stewart Fourth Annual Growth Conference on Thursday, July 10, 2008 at 10:30 AM ET, in New York.

The conference will take place at the Mandarin Oriental Hotel in New York City, from Tuesday, July 8 through Thursday, July 10. Insmed's presentation will be webcast live over the Internet and can be accessed directly on http://www.wsw.com/webcast/clst/insm/. The webcast will be archived for a period of 90 days.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing produ
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
2. Insmed Announces First Quarter 2008 Financial Results
3. Insmed to Present at CBI Follow-On Biologics Conference
4. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
5. Insmed Announces Additional Information in Compliance With NASDAQ Rules
6. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
9. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
10. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
11. Insmed to Appeal Delisting Notification From Nasdaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a ... appointment of Dr. Roger J Garceau, to its ... companies in matters including corporate development and clinical ... adds significant regulatory expertise as Fluorinov transitions to ... 30 years of pharmaceutical development experience to Fluorinov ...
(Date:5/4/2015)... May 04, 2015 Genedata, a ... discovery and life science research, today announced the ... latest version of its enterprise solution for biologics ... enables more efficient discovery and development of novel ... integrate and address protein optimization and developability requirements. ...
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
(Date:5/4/2015)... 2015   Intrexon Corporation (NYSE: XON ... financial results after the market closes on May 11, ... day at 5:30 PM ET to discuss the results ... conference call may be accessed by dialing 1-888-346-3959 (Domestic ... "Intrexon Conference Call."  Participants may also access the live ...
Breaking Biology Technology:Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2
... Benefiting from recent investments in production and enormous demand ... record quarter. The leading developer of topical biotechnology for hair ... over Q1 of 2010. It was the fastest growth since ... "Although Q1 delivered a stellar number — made ...
... Inc. ("Radius") today announced that the company has raised ... $66 million in equity financing and a commitment by ... to a $25 million multi-draw term loan facility. Five ... Capital, Nordic Bioscience ("Nordic"), and Ipsen Pharma SAS ("Ipsen") ...
... protein isolated from beneficial bacteria found in yogurt and ... for inflammatory bowel disorders (IBD), suggests a study led ... Ph.D. The study, published May 23 in the ... protein, called p40, was effective as an intervention in ...
Cached Biology Technology:First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 2First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 2Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 4Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5Protein from probiotic bacteria may alleviate inflammatory bowel disorders 2Protein from probiotic bacteria may alleviate inflammatory bowel disorders 3
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... mobile sequences of DNA left over from viruses, called transposons ... the genome, pose a significant threat to the genetic integrity ... elements are believed to comprise as much as 50 percent ... do to an organism,s DNA, an immune-like response has evolved ...
... generate millions of supercharged stem cells, which can then turn ... itself, has been patented at the University of Central Florida. ... holy grail of sorts in the medical world, because they ... of the most challenging diseases in our time, such as ...
... a simple, paper-based test for drug-resistant tuberculosis (TB) is ... chemist, whose project just received a $1.6 million point-of-care ... initiative created by the Bill & Melinda Gates Foundation. ... minds across scientific disciplines to work on solutions that ...
Cached Biology News:Defending the genome 2Defending the genome 3UCF patented on induced pluripotent stem cells, iPS cells 2University of Texas chemist receives major grant to improve detection of drug-resistant tuberculosis 2
...
... HyPer is the first fully genetically encoded ... of intracellular hydrogen peroxide (H2O2), one of ... on the basis of yellow fluorescent protein ... coli protein OxyR (OxyR-RD), HyPer demonstrates submicromolar ...
Alexa Fluor 647 anti-mouse Qa-2...
... cDNA normalization is essential for hunting ... high-throughput approaches, such as EST sequencing ... Evrogen TRIMMER-DIRECT kit is developed for ... sequences and intended for directional cloning. ...
Biology Products: